Medical Health & Life Science Research News

Cognitive impairment disorders market report for 2018 just published

Medical Market Research

The study of “Cognitive Impairment Disorders Market” provides the market size information, in-depth analysis along with competitive insights and segmentation.

Summary

 This report provides an overview of the pipeline landscape for cognitive impairment disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cognitive impairment associated with schizophrenia (CIAS), dementia, mild cognitive impairment and Alzheimer's disease, and features dormant and discontinued products.

These disorders are associated with impairments in cognitive abilities such as learning, memory and perception. Due to the complex and highly sophisticated nature of the central nervous system (CNS), the pathophysiology of these disorders is not well understood and treatment options remain limited.

Currently, marketed drugs act by slowing disease progression or treating symptoms.

Worldwide, the burden of cognitive impairment disorders will increase significantly in the coming decades due to aging populations. Consequently, there is a strong need to develop new therapies that effectively treat symptoms and target underlying mechanisms of disease.

Request a sample of this report @ orbisresearch.com/contacts/request-sample/2124080 .

Scope

- Which companies are the most active within the pipeline for cognitive impairment disorders?

- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened within this field?

Reasons to access

 - Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Access this report @ orbisresearch.com/contact/purchase/2124080 .

Companies Mentioned:

  • AB Science SA
  • AbbVie Inc
  • AC Immune SA
  • Acadia Pharmaceuticals Inc
  • Accera Inc
  • Acorda Therapeutics Inc
  • AgeneBio Inc
  • Alector LLC
  • Allergan Plc
  • Allgenesis Biotherapeutics Inc
  • Allinky Biopharma
  • ALSP Inc
  • Alzhyme Pty Ltd
  • Alzinova AB
  • CHA Bio & Diostech Co Ltd
  • Clera Inc
  • Cognition Therapeutics Inc
  • Cognosci Inc
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Daval International Ltd
  • Insys Therapeutics Inc
  • IntelGenx Corp
  • Intellect Neurosciences Inc
  • Intra-Cellular Therapies Inc

Browse the complete report @ orbisresearch.com/reports/index/co…line-review-2018 .

Some Points from Table of Content:

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 10

2 Introduction 12

2.1 Cognitive Impairment Disorders Report Coverage 12

2.2 Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 12

2.3 Dementia - Overview 12

2.4 Mild Cognitive Impairment - Overview 12

2.5 Alzheimer's Disease - Overview 12

3 Therapeutics Development 13

3.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 13

3.2 Dementia 18

3.3 Mild Cognitive Impairment 30

3.4 Alzheimer's Disease 36

4 Therapeutics Assessment 90

4.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 90

4.2 Dementia 97

4.3 Mild Cognitive Impairment 108

4.4 Alzheimer's Disease 116

5 Companies Involved in Therapeutics Development 140

5.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 140

5.2 Dementia 148

5.3 Mild Cognitive Impairment 173

5.4 Alzheimer's Disease 182

Make an enquiry of this report @ orbisresearch.com/contacts/enquiry…e-buying/2124080 .

6 Dormant Projects 286

6.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 286

6.2 Dementia 288

6.3 Mild Cognitive Impairment 292

6.4 Alzheimer's Disease 294

7 Discontinued Products 329

7.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 329

7.2 Dementia 330

7.3 Mild Cognitive Impairment 331

7.4 Alzheimer's Disease 332

8 Product Development Milestones 338

8.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 338

8.2 Dementia 339

8.3 Mild Cognitive Impairment 350

8.4 Alzheimer's Disease 357

9 Appendix 372

9.1 Methodology 372

9.2 Coverage 372

9.3 Secondary Research 372

9.4 Primary Research 372

9.5 Expert Panel Validation 372

9.6 Contact Us 372

9.7 Disclaimer 372

News From

Orbis Research - Rendering Conscientious ResearchOrbis Research
Category: Market Research Publishers and RetailersCompany about: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have a vast database of reports from the leading publishers and authors across the gl obe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their need, and we produce the perfect requi ...
This email address is being protected from spambots. You need JavaScript enabled to view it.